LUND, Sweden, March 3, 2025 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming […]
Tag: Immunovia AB
Immunovia Publishes Full Year Report for 2024
LUND, Sweden, Feb. 25, 2025 /PRNewswire/ — October-December 2024 Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155). Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange […]
Invitation to Immunovia’s Q4 presentation
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ — Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day […]
Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas–Inherited Gastrointestinal Cancers
PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ — Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of the […]
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ — Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of […]
